Orion Oyj (LON:0M2O)

Market Cap	7.68B
Revenue (ttm)	1.33B
Net Income (ttm)	290.62M
Shares Out	n/a
EPS (ttm)	2.07
PE Ratio	26.43
Forward PE	22.50
Dividend	1.37 (2.15%)
Ex-Dividend Date	Apr 4, 2025

Volume	110,321
Average Volume	68,382
Open	62.75
Previous Close	62.74
Day's Range	63.10 - 64.10
52-Week Range	38.08 - 64.15
Beta	0.37
RSI	69.43
Earnings Date	Jul 18, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 3,880
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M2O

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial numbers in EUR